A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | MicrobiomeTrials← Back to trialsNCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-05-06Est. Completion: 2026-12-01
Enrollment target: 100 participants Locations- TG Therapeutics Investigational Trial Site, La Jolla, California, United States
- TG Therapeutics Investigational Trial Site, Ann Arbor, Michigan, United States
- TG Therapeutics Investigational Trial Site, Omaha, Nebraska, United States
- TG Therapeutics Investigational Trial Site, New York, New York, United States
- TG Therapeutics Investigational Trial Site, Rochester, New York, United States
- TG Therapeutics Investigational Trial Site, Cleveland, Ohio, United States
- TG Therapeutics Investigational Trial Site, Columbus, Ohio, United States
- TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)Refractory PodocytopathyProliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
This study is a single-arm, open-label, dose-escalation and dose-expansion clinical trial, divided into two phases: the …
Shanghai, ChinaEst. completion Jun 30, 2028
Autoimmune Disorders
This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody pos…
Birmingham, United StatesEst. completion Aug 2028